No Data
Barclays Maintains Exscientia(EXAI.US) With Buy Rating, Maintains Target Price $10
Barclays analyst Peter Lawson maintains $Exscientia(EXAI.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 44.1% and a total a
Barclays Keeps Their Buy Rating on Exscientia Plc (EXAI)
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon
Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I
Exscientia to Reduce Up to 25% Workforce by Year End
Exscientia (EXAI) said Tuesday that it expects to complete a headcount reduction of 20% to 25% by the end of 2024. The job cuts are part of cost efficiency measures that the company will initiate to s
Express News | Exscientia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results
Tandem Diabetes Care, Guardion Health, GT Biopharma Among Healthcare Movers